Metagenomi Therapeutics is an in vivo genome editing company developing curative genetic medicines using proprietary gene editing systems derived from its metagenomics database to address limitations of conventional systems like CRISPR/Cas9. The company's lead program, MGX-001, is designed to provide one-time treatment for hemophilia A and other secreted protein deficiencies through targeted genome integration into hepatocytes. Metagenomi generates revenue through collaboration agreements with partners like Ionis and Acuitas, which provide upfront payments, development and regulatory milestone fees, and royalties on net sales, while advancing wholly-owned programs targeting rare genetic diseases with well-defined biological pathways and clear regulatory routes to approval.